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ABSTRACT
Thrombophilia includes multiple inherited and acquired risk factors that deter-
mine a shift in the balance of procoagulant and anticoagulant factors promoting hyper-
coagulability, which is associated with an increased risk of venous thromboembolism
(VTE). VTE is characterized by more common clinical manifestations, such as deep vein
thrombosis of the lower limbs or pulmonary embolism, and less common clinical
manifestations affecting cerebral, splanchnic, upper limbs, and retinal veins. The role of
inherited thrombophilia in the pathogenesis of VTE at unusual sites is better established in
cerebral vein thrombosis, but its role is less clear in splanchnic, upper limbs, and retinal vein
thrombosis, in which acquired risk factors such as malignancy, central venous catheters, or
systemic diseases also are frequently involved. The complex interactions between different
inherited and acquired thrombophilic risk factors and their relationship with endothelium
may be considered the pathophysiologic key of underlying phenotypic manifestations of
thrombosis. The understanding of these mechanisms might facilitate diagnosis with
appropriate investigations and improve therapeutic decision making.
KEYWORDS: Thrombophilia, thrombosis of the upper extremities, retinal vein
occlusion, cerebral vein thrombosis, splanchnic vein thrombosis
Venous thromboembolism (VTE) is a multi-
factorial disease in which multiple inherited and ac-
quired risk factors act synergistically determining
different thrombotic manifestations. Although throm-
bosis can potentially involve any section of the venous
system, common manifestations of VTE are deep vein
thrombosis (DVT) of the lower limbs and pulmonary
embolism. Uncommon manifestations of VTE affect
atypical sites, such as cerebral sinus, splanchnic, upper
limbs, and retinal veins. Different thrombotic manifes-
tations can result from different inherited and acquired
thrombophilic states. For example, the antiphospholi-
pid syndrome is associated with placenta thrombosis,1
myeloproliferative disorders are associated with ab-
dominal vein thrombosis,2 and the prothrombin muta-
tion G20210A (PTM) increases the risk of lower limb
thrombosis, portal vein thrombosis (PVT) and cerebral
vein thrombosis (CVT).3,4 In the complex pathophysi-
ology of different phenotypic manifestations of throm-
bosis, even the endothelium might play a critical role by
acquiring in response to different signals procoagulant
and anticoagulant properties that could be expressed
differently throughout the vascular tree.5 In recent
years, it became clear that congenital and acquired
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thrombophilia through complex interactions with the
vessel wall may induce alterations in the hemostatic
balance that predispose to thrombosis at unusual sites.
However, despite reasonable evidence that different
risk factors could lead to specific clinical manifestations
of VTE, most of these observations were derived from
small studies because of the relative rarity of thrombotic
events at unusual sites.
This review article focuses on the role of throm-
bophilia in the pathogenesis of unusual sites of VTE.
The interactions among different risk factors and the
strength of their associations in this field are also
discussed.
THROMBOSIS OF THE UPPER
EXTREMITIES
The incidence of upper extremities deep vein thrombosis
(UEDVT) is 10% of the total incidence of venous
thrombosis.6 UEDVT can be classified into different
categories according to its etiology: idiopathic, including
Paget-Schroetter syndrome or effort syndrome; and
secondary, in which a trigger or underlying disorder
such as indwelling intravenous catheters or neoplasms
can be identified. The clinical importance of UEDVT
has increased in recent years mainly due to the increasing
use of central venous catheters (CVCs), which are an
important risk factor. Until a decade ago, the prevalence
was low, with an estimated range from 1% to 4%.7
Idiopathic UEDVT accounts for 10 to 30% of all
cases,8,9 and strenuous muscular effort is detected in
one fourth of primary cases.10 The Paget-Schroetter
syndrome or effort syndrome is a pinching of the
axillary–subclavian vein at the thoracic outlet by muscu-
lar and osteo-tendinous structures induced by abduction
and extension of the arm determining a mechanical
obstruction. The compression of the axillary–subclavian
vein is physiologic but it may be aggravated by anatom-
ical abnormalities or by repetitive compression, given
that it usually happens during sports or occupational
activities, leading to endothelial damage and inflamma-
tion11 and to the development of venous thrombosis.
This form of UEDVT is frequently reported in ath-
letes,12 and patients usually are apparently healthy young
males.13,14
The prevalence of inherited thrombophilia in
patients with primary UEDVT ranges from 10% to
20%.9,10,13–15 Martinelli et al10 showed after multivariate
analysis a 5- to 6-fold increased risk for factor V Leiden
mutation (FVL) and PTM, respectively, and a 5-fold
increased risk for natural inhibitors (antithrombin, pro-
tein C, and protein S deficiency) considered together,
whereas there was no association with hyperhomocys-
teinemia. Blom et al9 found a 3-fold increased risk for
the combination of FVL and PTM. In line with these
studies, two small studies with 51 and 31 consecutive
patients, respectively, also found a high prevalence of
thrombophilic defects in UEDVT patients.13,14 For
patients with a history of strenuous muscular effort the
association with thrombophilia is less clear, but this
could be due to the small size of the studies.10,13,14
The presence of antiphospholipid antibodies in patients
with primary UEDVT varies from 8 to 31%,10,13–15 but
it is approximately 8% in two studies with a larger series
of patients.10,15 Another important risk factor for appa-
rently idiopathic UEDVT is an occult malignancy,
which can be diagnosed in about one fourth of cases
within 1 year of follow-up.16
Secondary cases of UEDVT are more common
than primary cases and are more frequent in older and
hospitalized patients.6,8,14,17 The most important risk
factors are the presence of CVC (accounting for up to
70% of secondary cases),6,8,9,17,18 and cancer (diagnosed
in up to 61% of cases).8,9,17–19 The presence of FVL and
PTM mutations seems to increase the risk of CVC-
related thrombosis, with an odds ratio (OR) of 2.7 (95%
confidence interval [CI], 1.9 to 3.8).20 Different studies
showed a synergistic effect in increasing the risk of
UEDVT between oral contraceptives (OCs) and throm-
bophilia of up to 9-fold (95% CI, 2.8 to 30.2).9,10,15 A
recent review reported an important link between
UEDVT and pregnancies achieved with the use of
assisted reproductive techniques in which the higher
incidence of thrombosis involving the internal jugular
vein (81%) has not yet been understood.21 Inherited
thrombophilia was detected in 41% of these women, but
the limitation is that these data are derived mainly from
case reports.21
The decision to carry out routine testing for
inherited thrombophilia among patients with an episode
of either primary or secondary UEDVT is controversial
for at least two reasons: (1) the increased risk of recur-
rence determined by thrombophilia is not well known
and it seems to be modest10; and (2) clinical implications
of thrombophilia such as prophylactic or optimal dura-
tion of anticoagulation are unknown. Considering the
possible synergistic effects between genetic thrombo-
philia and environmental risk factors, such as OCs, young
patients with unexplained or hormone-related DVT
could be advised about screening for thrombophilia.
RETINAL VEIN OCCLUSION
Retinal vein occlusion (RVO) is a paradigm of complex-
ity of VTE that results from multiple and synergistic risk
factors, including local factors and systemic diseases, that
determine the thrombogenic conditions of the Virchow’s
triad, such as stasis, vessel wall damage, and hyper-
coagulability. RVO is the most common vascular disease
of the eye and is the main cause of visual loss after
diabetes. The incidence rate of RVO is 0.5 per 1,000
persons older than 40 years and increases significantly



















































with age,22 with more than 50% of patients older than
65 years.23 RVO can be classified accordingly to the site
of occlusion into branch RVO, hemicentral RVO, and
central retinal vein occlusion (CRVO). CRVO affects
the venous flow of the entire retina, determining a more
severe clinical picture. Local risk factors of RVO include
open-angle glaucoma, ocular hypertension (which af-
fects up to 43% of patients), and local inflammation.24
An anatomical factor involved in the pathophysiology of
RVO is the course of the vessels through the lamina
cribrosa, which can degenerate with aging, causing a
mechanical obstruction leading to endothelial damage.
Systemic diseases associated with a higher incidence of
RVO are hypertension, diabetes, dyslipidemia, increased
blood viscosity, and cardiovascular diseases.25–29 The
potential role of thrombophilia in the development of
RVO is still unclear, with conflicting results in the
literature; however, it seems to be marginal. A recent
meta-analysis30 assessed the prevalence of thrombophilia
among patients with RVO. The included studies often
were retrospective, with a limited number of patients.
FVL was evaluated in 14 case-control studies and had an
overall OR for RVO of 1.5 (95% CI, 1.0 to 3.2).30 In
most studies the incidence of FVL was not significantly
higher in patients with RVO. The role of PTM in RVO
also seemed marginal (OR, 1.6; 95% CI, 0.8 to 1.6).30 In
five studies, none of the patients and in one study none
of the controls were carriers of PTM.30 Deficiencies of
natural inhibitors were scarce and not associated signifi-
cantly with RVO.30 Hyperhomocysteinemia had an
overall OR of 8.9 (95% CI, 5.7 to 13.7), derived from
11 studies that included a total of 527 cases and 955
controls.30 Thermolabile variant of methylenetetrahy-
drofolate reductase (MTHFR) was not associated with
RVO (overall OR, 1.2; 95% CI, 0.9 to 1.6).30 The
overall OR for combined anticardiolipin immunoglobu-
lin (Ig) M and IgG from seven case-control studies was
3.9 (95% CI, 2.3 to 6.7), whereas the role of lupus
anticoagulant was unclear.30 Table 1 reports the main
results found in Janssen meta-analysis.30
A study of 234 consecutive patients with RVO
confirmed that the frequency of FVL was similar be-
tween cases and controls, with a slight increased preva-
lence in the subgroup of patients younger than
60 years.31 In the same study, the prevalence of PTM
was not significantly different between cases and con-
trols.31 In line with the aforementioned meta-analysis, a
large cross-sectional study confirmed the association
between high plasma homocysteine levels and RVO in
patients younger than 70 years, with an OR of 3.76 (95%
CI, 1.06 to 13.40).32 In contrast, two recent case-control
studies failed to demonstrate an association between
increased levels of homocysteine and RVO.33,34
In conclusion, the role of thrombophilia in RVO
is unclear and therefore routine testing for the presence
of genetic thrombophilia is probably not advisable.
Increased plasma levels of homocysteine may be an
important risk factor, but this may reflect systemic
inflammation, which is associated with cardiovascular
risk factors. Atherosclerotic risk factors, such as hyper-
tension and diabetes, play an important role in the
development of RVO, and recently, RVO has been
associated with a more than 2-fold increased risk of
cardiovascular mortality.35
CEREBRAL VEIN THROMBOSIS
CVT is a rather uncommon disease. However, thanks to
the general availability of noninvasive techniques, in the
last few years CVT is diagnosed more frequently, and
less clinically severe cases of CVT are detected. In
previous studies, the majority of CVTs were found to
be secondary to local or systemic infections, and more
than 30% of cases of CVT were considered idio-
pathic.36,37 However, more recent studies reported other
risk factors, such as thrombophilia or the use of OCs to
be associated with CVT.38,39
The prevalence of thrombophilic abnormalities in
patients with CVT has been evaluated only in small
studies and the results are often conflicting or not
conclusive. Our group recently has published a system-
atic review and a meta-analysis of the studies that
analyzed the association between CVT and the most
frequent thrombophilic conditions.4 A total of 17 studies
were included in the analysis. We found a strong
association between both FVL and the PTM, and
CVT. In detail, 13 studies including 469 cases and
3023 controls evaluated the role of FVL and nine studies
including 360 cases and 2688 controls evaluated the role
of PTM in patients with CVT. FVL was associated with
Table 1 Summary of the Results of the Meta-Analysis on Association between Thrombophilia and RVO30







Factor V Leiden 1.5 (1.0–2.2) 14 792 1418
G20210A mutation of prothrombin 1.6 (0.8–3.2) 12 700 1334
Hyperhomocysteinemia 8.9 (5.7–13.7) 11 527 955
MTHFR 1.2 (0.9–1.6) 10 581 1080
Anticardiolipin antibodies 3.9 (2.3–6.7) 7 412 508
RVO, retinal vein occlusion; OR, odds ratio; CI, confidence interval; MTHFR, thermolabile variant of methylenetetrahydrofolate reductase.



















































CVT, with an OR of 3.38 (95% CI, 2.27 to 5.05); PTM
was associated with CVT, with an OR of 9.27 (95% CI,
5.85 to 14.67). We also found an equally strong associ-
ation between CVT and hyperhomocysteinemia (OR,
4.07; 95% CI, 2.54 to 6.52), although only four studies
were actually retrieved.
Data on antiphospholipid antibodies syndrome
and on deficiencies of antithrombin, protein C, and
protein S were inadequate to allow any conclusions.
Two studies analyzed the role of deficiencies of antith-
rombin, protein C, and protein S as risk factors for
CVT.40,41 The combined OR of the two studies was
2.69 for antithrombin (95% CI, 0.66 to 10.96), 11.10 for
protein C (95% CI, 1.87 to 66.05), and 12.49 for protein
S (95% CI, 1.45 to 107.29; p¼ 0.03).40,41 Because of the
low number of eligible patients, the confidence intervals
are very wide. Only one study considered antiphospho-
lipid syndrome40 and one study included anticardiolipin
antibodies alone.42 In the first study,40 the prevalence of
antiphospholipid antibodies was higher in CVT patients
(nine of 121) compared with controls (zero of 242). In
the second study,42 the authors found a significantly
higher incidence of positive anticardiolipin antibodies in
CVT patients (seven of 31) in comparison with controls
(one of 31; OR, 8.75; 95% CI, 1.01 to 75.64). Table 2
summarizes the results of the aforementioned meta-
analysis.4
The risk of CVT in women of reproductive age
taking OCs and with concomitant thrombophilic con-
ditions was evaluated in two studies.40,43 Martinelli
et al40 found an OR of 19.5 (95% CI, 5.7 to 67.3) in
the presence of hyperhomocysteinemia, an OR of 30.0
(95% CI, 3.4 to 263.0) in the presence of FVL mutation,
and an OR of 79.3 (95% CI, 10.0 to 629.4) in the
presence of PTM as compared with control women
without any thrombophilic condition. A similar result
was observed in a study performed by Gadelha et al,43 in
which a multivariate analysis proved the independent
association between CVT, PTM, and the use of OCs.
The role of other thrombophilic abnormalities
was investigated in CVT patients in recent studies.
Bugnicourt et al44 found significantly higher levels of
factor VIII and von Willebrand factor in 16 CVT
patients in comparison with controls. Conversely, Lichy
et al found no significant association between CVT and a
single nucleotide polymorphism of the thrombin acti-
vatable fibrinolysis inhibitor, and between CVT and the
protein Z gene mutation (intron F G79A), which is
linked with low protein Z levels.45
In conclusion, CVT appears to be strongly asso-
ciated with the FVL mutation, with the PTM
G20210A, and with hyperhomocysteinemia. The role
of the other thrombophilic abnormalities in the patho-
genesis of CVT remains to be clarified.
SPLANCHNIC VEIN THROMBOSIS
Splanchnic vein thrombosis (SVT) is an uncommon but
potentially life-threatening disease. Mesenteric vein
thrombosis (MVT), PVT, and Budd-Chiari syndrome
(BCS) are three autonomous diseases, but the involve-
ment of two or more different abdominal vein segments
is common.
Because symptoms are nonspecific, diagnosis of
SVT is difficult and its true incidence is likely under-
estimated. However, advances in imaging techniques,
especially Doppler ultrasonography and computed to-
mography, have facilitated its early diagnosis. Acquired
causes of SVT vary according to the site of thrombosis.
For MVT, the most common causes are cancer, intra-
abdominal inflammatory conditions (pancreatitis, abscess,
inflammatory bowel disease, diverticulitis), postoperative
state, liver cirrhosis, and portal hypertension.46 For
PVT, the most common causes are included liver cirrho-
sis, hepatocellular carcinoma, and myeloproliferative
disorders.47
Only few studies have examined the role of
thrombophilia in patients with SVT. Janssen et al
performed a case-control study in which they investi-
gated the prevalence of FVL, PTM, and of inherited
deficiencies of protein C, protein S, and antithrombin in
43 patients with BCS, in 92 patients with PVT, and in
474 population-based controls.48 Among the BCS pa-
tients, FVL (OR, 11.3; 95% CI, 4.8 to 26.5) and
Table 2 Summary of the Results of the Meta-Analysis on Association between Thrombophilia and CVT4







Factor V Leiden 3.38 (1.27–5.05) 13 469 3023
G20210A mutation of prothrombin 9.27 (5.85–14.67) 9 360 2688
Hyperhomocysteinemia 4.07 (2.54–6.52) 4 222 472
Protein C 11.10 (1.87- 66.05) 2 147 362
Protein S 12.49 (1.45–107.29) 2 147 362
Antithrombin 2.69 (0.66–10.96) 2 172 362
Antiphospholipid antibodies syndrome 40.96 (2.36–709.87) 1 121 242
Anticardiolipin antibodies 8.75 (1.01–75.64) 1 31 31
CVT, cerebral vein thrombosis; OR, odds ratio; CI, confidence interval.



















































inherited deficiency of protein C (OR, 6.8; 95% CI, 1.9
to 24.4) were more prevalent than in controls, whereas
the prevalence of PTM was not different in comparison
to controls and no patient had an inherited deficiency of
protein S or antithrombin. Similarly, among the PVT
patients, FVL (OR, 2.7; 95% CI, 1.1 to 6.9) and
inherited deficiency of protein C (OR, 4.6; 95% CI,
1.5 to 14.1) were again more prevalent than in controls,
whereas the prevalence of PTM and of inherited defi-
ciency of protein S or antithrombin was not different in
comparison to controls. The use of OCs was an impor-
tant acquired risk factor for both BCS and PVT, given
that 12 of 20 BCS women (60%) and 12 of 25 PVT
women (48%) between 15 and 49 years had been using
OCs at the time of diagnosis in comparison to 65 of 169
controls (38%). In another recent study, Primignani
et al3 evaluated the prevalence of FVL, PTM, hyper-
homocysteinemia, and deficiency of protein C, protein S,
and antithrombin in 65 patients with extrahepatic portal
vein obstruction and in 700 healthy controls. They found
an association among PTM (OR, 8.1; 95% CI, 3.8 to
17.5), deficiency of protein C, protein S, or antithrombin
taken together (OR, 4.5; 95% CI, 1.1 to 18.0), and portal
vein obstruction, whereas the prevalence of hyperhomo-
cysteinemia was not different in comparison to controls.
In contrast to the study conducted by Janssen,48 the
prevalence of FVL was not different between cases and
controls, and the use of OCs was not associated with an
increased risk of portal vein obstruction, given that OCs
were used in a similar proportion of patients and controls
(26% and 28%, respectively). Recently, Amitrano et al49
evaluated the prevalence of common thrombophilic
abnormalities in 12 patients with MVT and in 431
healthy controls. FVL (OR, 6.2; 95% CI, 1.6 to 24.5),
PTM (OR, 6.9; 95% CI, 1.7 to 27.3), and MTHFR
TT677 genotype (OR, 4.5; 95% CI, 1.4 to 14.4) were
associated with an increased risk of MVT, whereas
anticardiolipin antibodies, lupus anticoagulant, and
deficiency of protein C, protein S, and antithrombin
were not.
In conclusion, the results of these studies seem to
suggest a potential role of thrombophilic abnormalities in
the pathogenesis of SVT. However, the role of a single
thrombophilic abnormality cannot be assessed because
the prevalence and the role of these factors in patients
with SVT have been evaluated only in small studies and
the results are often conflicting or inconclusive.
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